Eli Lilly and Company
LLY
$1,189.41
-$44.25-3.59%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.56% | 127.60% | 94.90% | 119.98% | 87.96% |
| Total Depreciation and Amortization | 10.87% | 11.66% | 13.00% | 13.58% | 17.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.13% | -113.21% | 23.01% | 3.09% | 186.81% |
| Change in Net Operating Assets | 38.94% | 8.63% | -50.31% | -4.90% | -42.17% |
| Cash from Operations | 156.73% | 119.80% | 90.67% | 166.28% | 142.56% |
| Capital Expenditure | -63.42% | -55.10% | -55.03% | -46.60% | -42.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -3,488,566.67% | -81.33% | 30.27% | 72.40% | 99.98% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.35% | 76.59% | 25.08% | 25.29% | -61.25% |
| Cash from Investing | -125.84% | -0.50% | -17.95% | 2.08% | -18.46% |
| Total Debt Issued | 83.20% | -25.77% | 15.33% | -17.76% | 2.53% |
| Total Debt Repaid | -433.56% | -578.33% | -103.34% | 62.70% | -10.32% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -40.55% | -42.26% | -64.31% | -943.26% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.97% | -15.01% | -15.04% | -14.92% | -14.98% |
| Other Financing Activities | 19.74% | 13.96% | -57.29% | -66.37% | -85.74% |
| Cash from Financing | 2,059.11% | -341.77% | -279.90% | -91.19% | -97.75% |
| Foreign Exchange rate Adjustments | -109.95% | 336.76% | 225.12% | -96.21% | 419.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,567.43% | 246.22% | 790.98% | 549.93% | -71.27% |